Arca
Skip to content
Tools
Tools

Heart failure

Drug research and approvals for heart failure: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 1,022 studies of heart failure are recruiting on ClinicalTrials.gov, Health Canada has authorized 101 drug trials for it since 2013, FDA has 1 approved and 3 open orphan designations naming it, and the EU has 6 authorised medicines for it.

  • Recruiting worldwide: 1,022
  • Trials authorized in Canada: 101
  • FDA orphan approvals: 1
  • EU medicines: 6

Recruiting now

Newest posted first, of 1,022 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 24 of 46

Phase 3 12 of 57

Phase 2 12 of 80

Phase 1 or earlier 12 of 36

How its trials ended

5,179 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 1,268 whose ending is known, 37% met their primary endpoint, 12% missed it and 52% stopped early.

  • Completed, result not reported1,98738%
  • Ongoing1,13022%
  • Status unknown79415%
  • Met its primary endpoint4639%
  • Stopped: other or unclear3487%
  • Stopped: enrollment or feasibility1693%
  • Missed its primary endpoint1503%
  • Stopped: sponsor or business decision561%
  • Stopped: lack of efficacy391%
  • Stopped: funding331%
  • Stopped: safety10<1%

Trials authorized in Canada

The 10 newest of 101; search them all in Canada trials
Oct 29, 2026A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sotatercept in adults with combined postcapillary and…Winrevair (sotatercept (MK-7962))Merck & Co. (MSD)Pending
Jul 13, 2026A multicenter, open-label, long-term extension study for oral levosimendan (TNX-103)Levosimendan (TNX-103)Tenax TherapeuticsPending
Jun 23, 2026Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of 2 dose levels of the oral ghrelin…AC01 (HM01)Anacardio ABPending
May 12, 2026A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the effect of elecoglipron in reducing cardiovascular…Elecoglipron (AZD5004) / DapagliflozinAstraZeneca PharmaceuticalsOngoing
Mar 19, 2026Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection…NNC0487-0111Novo NordiskOngoing
Dec 5, 2025A multi-center, randomized, participant- and investigator- blinded, placebo-controlled crossover study to investigate the safety, tolerability, and…HJB647Novartis PharmaceuticalsOngoing
Oct 28, 2025Oral l-carnitine supplementation in cardiorenal heart failure patientsLevocarnitineLondon Health Sciences CentreOngoing
Aug 29, 2025A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to investigate the efficacy, safety, and pk/ pd of finerenone, in addition to…Finerenone (bay 94-8862)BayerOngoing
Aug 29, 2025A phase 3, single-arm, open-label extension study to evaluate the safety of finerenone in addition to standard of care, in pediatric heart failure patients,…Finerenone (bay 94-8862)BayerOngoing
Jun 25, 2025A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of maridebart cafraglutide on mortality and morbidity in…Maridebart cafraglutide (amg 133)AmgenOngoing

FDA orphan designations

Approved first, then open designations, newest first
Apr 22, 2019CorlanorCorlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged…Amgen, Inc.,Approved
Jan 8, 2018MilrinoneTreatment of right heart failure (RHF) in left ventricular assist device (LVAD) patientsHyloris Developments SADesignated
Nov 2, 2004Sitaxsentan SodiumFor the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.Pfizer Global Research and DevelopmentDesignated
Apr 12, 2004Ubiquinol, coenzyme Q10, ubiquinoneTreatment of pediatric congestive heart failureGel-Tec, Division of Tishcon CorporationDesignated

Medicines authorised in the EU

Newest first
Nov 15, 2023AqumeldiEnalapril maleateProveca Pharma LimitedEMA ↗
Jul 16, 2021VerquvoVericiguatBayer AGEMA ↗
Apr 19, 2017RoteasEdoxabanBerlin-Chemie AGEMA ↗
May 26, 2016NeparvisSacubitril; valsartanNovartis Europharm LimitedEMA ↗
Nov 19, 2015EntrestoSacubitril; valsartanNovartis Europharm LimitedEMA ↗
Jun 19, 2015LixianaEdoxabanDaiichi Sankyo Europe GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.